Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Bristol-Myers Squibb Company ( BMY) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 1.0%. By the end of trading, Bristol-Myers Squibb Company fell $1.05 (-1.9%) to $55.56 on average volume. Throughout the day, 7,948,619 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8,659,800 shares. The stock ranged in price between $55.54-$57.49 after having opened the day at $56.28 as compared to the previous trading day's close of $56.61. Other companies within the Health Care sector that declined today were: Zogenix ( ZGNX), down 14.5%, Cardiome Pharma Corporation ( CRME), down 11.7%, Kamada ( KMDA), down 11.3% and AVANIR Pharmaceuticals ( AVNR), down 11.0%.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Bristol-Myers Squibb Company has a market cap of $93.1 billion and is part of the drugs industry. Shares are up 6.2% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 2 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Agios Pharmaceuticals ( AGIO), up 26.2%, Sangamo BioSciences ( SGMO), up 17.1%, Karyopharm Therapeutics ( KPTI), up 13.9% and La Jolla Pharmaceutical ( LJPC), up 12.7% , were all gainers within the health care sector with Align Technology ( ALGN) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Bristol-Myers Squibb Stock Still a Beast?

There Are Good Opportunities in Stock Picking

Halozyme Jumps on Immuno-Oncology Deal with Bristol-Myers

Achillion Shares Are Plunging on Termination of Hepatitis C Pact